A new study now finds that people who inject drugs have a significant increase in the risk of infective endocarditis. It is a serious infection of the lining of the heart and is possibly linked to increased use of the opioid hydromorphone.
The study is published in Canadian Medical Association Journal (CMAJ).
Speaking about the study, first author Dr, Matthew Weir wrote, "We observed a substantial increase in the risk of infective endocarditis among people who inject drugs, which is associated with hydromorphone's increasing share of the prescription opioid market."
The study further found that although admission rates for people who inject drugs were stable over the study period, the risk of infective endocarditis increased from 13.4 admissions every three months (fourth quarter 2011) to 35.1 admissions every three months in the period afterwards.
Whereas the percentage of opioid prescriptions attributed to controlled-release oxycodone declined rapidly when it was removed from the market by its manufacturer in the fourth quarter of 2011, hydromorphone prescriptions increased from 16 per cent at the start of the study to 53 per cent by the end.
The researchers expected that an increase in risk of infective endocarditis would occur when controlled-release oxycodone was removed from the Canadian market; however, they found that the rise began before removal.
Speaking about it, co-author Dr. Michael Silverman said, "Although our observations do not support our hypothesis that the loss of controlled-release oxycodone increased the use of hydromorphone, they do support our suspicion that hydromorphone may be playing a role in the increasing risk of infective endocarditis."
The increase in the risk of infective endocarditis is consistent with the findings of other studies, but the observed timing of the increase was novel.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
